Dr. Armendáriz is recognized globally as one of the leading figures in the field of hepatology and as a pioneer in gene therapy. In addition to his contributions to Tecnológico de Monterrey, Dr. Armendáriz has collaborated for more than 25 years at the University of Guadalajara, where he became Full Professor "C", founder of the Department of Molecular Biology and Genomics, as well as founder and director of the Institute of Molecular Biology in Medicine at said university, one of the first programs in Mexico in what is now called Genomic Medicine. He has also been a visiting professor at the University of Florence, in Italy. 

A Level III Emeritus Researcher of the Mexican National System of Researchers, much of Dr. Armendáriz's research has focused on the cellular and molecular basis of the treatment of liver cirrhosis and renal glomerulosclerosis.

As a result of his research, he has published more than 200 scientific articles, has presented more than 470 papers in national and international congresses, and has played leadership roles in the National Commission for the Human Genome, the Mexican Academy of Science, and the National Academy of Medicine (Mexico).

Among the most relevant recognitions of his career is the National Science Award "Mario Molina", obtained in 2023. 

Dr. Armendáriz joined Tecnológico de Monterrey as a Distinguished Professor in Biomedical Sciences for the School of Medicine and Health Sciences. 

• Post-doctorate in Molecular Biology, University of Tennessee
• PhD Biochemistry, CINVESTAV, Instituto Politécnico Nacional 
• Master in Biochemistry, CINVESTAV, Instituto Politécnico Nacional

Dr. Armendáriz is recognized globally as one of the leading figures in the field of hepatology and as a pioneer in gene therapy. In addition to his contributions to Tecnológico de Monterrey, Dr. Armendáriz has collaborated for more than 25 years at the University of Guadalajara, where he became Full Professor "C", founder of the Department of Molecular Biology and Genomics, as well as founder and director of the Institute of Molecular Biology in Medicine at said university, one of the first programs in Mexico in what is now called Genomic Medicine. He has also been a visiting professor at the University of Florence, in Italy. 

A Level III Emeritus Researcher of the Mexican National System of Researchers, much of Dr. Armendáriz's research has focused on the cellular and molecular basis of the treatment of liver cirrhosis and renal glomerulosclerosis.

As a result of his research, he has published more than 200 scientific articles, has presented more than 470 papers in national and international congresses, and has played leadership roles in the National Commission for the Human Genome, the Mexican Academy of Science, and the National Academy of Medicine (Mexico).

Among the most relevant recognitions of his career is the National Science Award "Mario Molina", obtained in 2023. 

Dr. Armendáriz joined Tecnológico de Monterrey as a Distinguished Professor in Biomedical Sciences for the School of Medicine and Health Sciences. 

• Post-doctorate in Molecular Biology, University of Tennessee
• PhD Biochemistry, CINVESTAV, Instituto Politécnico Nacional 
• Master in Biochemistry, CINVESTAV, Instituto Politécnico Nacional

Dr. Alejandro Madrigal began his medical studies at the Universidad Nacional Autónoma de México (UNAM) and continued his training at some of the world’s top universities. He is currently a Professor of Hematology at UCL, a Faculty of Excellence professor at the Tecnológico de Monterrey, and a Professor Emeritus of the National System of Researchers in Mexico. He was an Honorary Affiliated Physician at the Royal Free Hospital (UK) and UCL Cancer Institute.

He founded and served as the first scientific director of the Anthony Nolan Research Institute in London, which supports people with blood cancer or disorders. He has trained numerous doctors and scientists and has developed multiple Registers for Unrelated Stem Cell Donors (USCD) and cord blood collection centers. His research focuses on how to improve immunotherapy and stem cell transplantation to make cancer cell therapy more accessible, particularly for minorities. He is a Fellow of the Academy of Medical Sciences and a member of the Royal College of Physicians (UK) and holds honorary memberships in the National Academy of Medicine (Mexico) and the Mexican Academy of Sciences.

He has secured multiple grants and has funded students and researchers. He has published over 570 papers, with more than 17,000 citations in journals like Nature and The Lancet. In 2023, he received the Carlos Slim Health Award for Lifetime Achievement in Research for his work on health issues in Latin America. He also holds four honorary doctorates and was appointed an Officer of the Most Excellent Order of the British Empire (OBE) by Queen Elizabeth II in 2022.

Alejandro Madrigal joined Tecnológico de Monterrey as a FEMSA Distinguished Professor in Hematology and Cellular Therapy for the School of Medicine and Health Sciences.

• Postdoctoral studies, Harvard University
• Postdoctoral studies, Stanford University
• Doctoral studies, University College London (UCL)
• Medicine and specialty in Internal Medicine, Universidad Nacional Autónoma de México (UNAM)

• Madrigal, J. A., Chávez, M., & Mayani, H. (2022). Advanced Cell Therapy: Beyond the last Frontier in the Treatment of Cancer. A Historical Perspective Emphasizing the Work of Nobel Prize Laureates. Archives Of Medical Research, 53(8), 747-752. https://doi.org/10.1016/j.arcmed.2022.11.006

• Ros-Soto, J., Snowden, J. A., Szydlo, R., Nicholson, E., Madrigal, A., Easdale, S., Potter, M., Ethell, M., & Anthias, C. (2022). Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter. Transplantation And Cellular Therapy, 28(4), 183.e1-183.e8. https://doi.org/10.1016/j.jtct.2022.01.022

• Petersdorf, E. W., Gooley, T., Volt, F., Kenzey, C., Madrigal, A., McKallor, C., Querol, S., Rafii, H., Rocha, V., Tamouza, R., Chabannon, C., Ruggeri, A., & Gluckman, É. (2020). Use of the HLA-B leader to optimize cord blood transplantation. Haematologica, 106(12), 3107-3114. https://doi.org/10.3324/haematol.2020.264424

• Querol, S., Rubinstein, P., & Madrigal, A. (2021). The wider perspective: cord blood banks and their future prospects. British Journal Of Haematology, 195(4), 507-517. https://doi.org/10.1111/bjh.17468

• Wynn, L. A., & Madrigal, A. (2021). Predictive analytics and cord blood banking: toward utilization-based unit selection. Cytotherapy, 23(7), 641-646. https://doi.org/10.1016/j.jcyt.2021.01.002

More information

Dr. Alejandro Madrigal began his medical studies at the Universidad Nacional Autónoma de México (UNAM) and continued his training at some of the world’s top universities. He is currently a Professor of Hematology at UCL, a Faculty of Excellence professor at the Tecnológico de Monterrey, and a Professor Emeritus of the National System of Researchers in Mexico. He was an Honorary Affiliated Physician at the Royal Free Hospital (UK) and UCL Cancer Institute.

He founded and served as the first scientific director of the Anthony Nolan Research Institute in London, which supports people with blood cancer or disorders. He has trained numerous doctors and scientists and has developed multiple Registers for Unrelated Stem Cell Donors (USCD) and cord blood collection centers. His research focuses on how to improve immunotherapy and stem cell transplantation to make cancer cell therapy more accessible, particularly for minorities. He is a Fellow of the Academy of Medical Sciences and a member of the Royal College of Physicians (UK) and holds honorary memberships in the National Academy of Medicine (Mexico) and the Mexican Academy of Sciences.

He has secured multiple grants and has funded students and researchers. He has published over 570 papers, with more than 17,000 citations in journals like Nature and The Lancet. In 2023, he received the Carlos Slim Health Award for Lifetime Achievement in Research for his work on health issues in Latin America. He also holds four honorary doctorates and was appointed an Officer of the Most Excellent Order of the British Empire (OBE) by Queen Elizabeth II in 2022.

Alejandro Madrigal joined Tecnológico de Monterrey as a FEMSA Distinguished Professor in Hematology and Cellular Therapy for the School of Medicine and Health Sciences.

• Postdoctoral studies, Harvard University
• Postdoctoral studies, Stanford University
• Doctoral studies, University College London (UCL)
• Medicine and specialty in Internal Medicine, Universidad Nacional Autónoma de México (UNAM)

• Madrigal, J. A., Chávez, M., & Mayani, H. (2022). Advanced Cell Therapy: Beyond the last Frontier in the Treatment of Cancer. A Historical Perspective Emphasizing the Work of Nobel Prize Laureates. Archives Of Medical Research, 53(8), 747-752. https://doi.org/10.1016/j.arcmed.2022.11.006

• Ros-Soto, J., Snowden, J. A., Szydlo, R., Nicholson, E., Madrigal, A., Easdale, S., Potter, M., Ethell, M., & Anthias, C. (2022). Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter. Transplantation And Cellular Therapy, 28(4), 183.e1-183.e8. https://doi.org/10.1016/j.jtct.2022.01.022

• Petersdorf, E. W., Gooley, T., Volt, F., Kenzey, C., Madrigal, A., McKallor, C., Querol, S., Rafii, H., Rocha, V., Tamouza, R., Chabannon, C., Ruggeri, A., & Gluckman, É. (2020). Use of the HLA-B leader to optimize cord blood transplantation. Haematologica, 106(12), 3107-3114. https://doi.org/10.3324/haematol.2020.264424

• Querol, S., Rubinstein, P., & Madrigal, A. (2021). The wider perspective: cord blood banks and their future prospects. British Journal Of Haematology, 195(4), 507-517. https://doi.org/10.1111/bjh.17468

• Wynn, L. A., & Madrigal, A. (2021). Predictive analytics and cord blood banking: toward utilization-based unit selection. Cytotherapy, 23(7), 641-646. https://doi.org/10.1016/j.jcyt.2021.01.002

More information